Salivary gland atrophy is a frequent consequence of head and neck cancer irradiation therapy but can potentially be regulated through the mammalian target of rapamycin (mTOR). Excretory duct ligation of the mouse submandibular gland provokes severe glandular atrophy causing activation of mTOR. This study aims to discover the effects of blocking mTOR signaling in ligation-induced atrophic salivary glands. Following 1 week of unilateral submandibular excretory duct ligation: gland weights were significantly reduced, 4E-BP1 and S6rp were activated, and tissue morphology revealed typical signs of atrophy. However, 3 days following ligation with rapamycin treatment, a selective mTOR inhibitor, gland weights were maintained, 4E-BP1 and S6rp phosphorylation was inhibited, and there were morphological signs of recovery from atrophy. However, following 5 and 7 days of ligation and rapamycin treatment, glands expressed active mTOR and showed signs of considerable atrophy. This evidence suggests that inhibition of mTOR by rapamycin delays ligation-induced atrophy of salivary glands. Approximately 500 000 people worldwide are diagnosed with head and neck cancer every year.
2,3
Salivary gland atrophy can be recreated experimentally in rodents via ligation of the main excretory duct of the submandibular gland, which creates a histological appearance comparable with that which occurs in humans, 4 which involves deletion of acinar cells through apoptosis 5 and autophagy, 6 as well as mitotic proliferation of ductal cells. 5 One potentially important mechanism of regulating atrophy in salivary gland and other tissues is through the mammalian target of rapamycin; 7 a highly conserved serine/threonine protein kinase which integrates cues from nutrients and growth factors, acting as a nexus point for cellular signals to control growth, metabolism and longevity. Activated mTOR regulates protein synthesis by phosphorylating ribosomal S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) 8 at multiple sites. 9 Although in normal circumstances, mTOR is switched on in some tissues such as muscle and liver, it is normally switched off in salivary glands. mTOR is potentially instrumental in controlling acinar and ductal atrophy as it gets switched on after duct ligationinduced atrophy in the animal model, 10 however the role of mTOR in ligation-induced atrophy of salivary glands is still not fully clear.
Rapamycin is a specific inhibitor of mTOR signaling that binds directly to the mTOR complex 1 (mTORC1) and suppresses mTOR-mediated phosphorylation of S6K1 and 4E-BP1. 8 In the present study, rapamycin was used to study the effects of mTOR inhibition on duct ligation-induced salivary gland atrophy.
Results
Gland weights. Mean submandibular gland weight was significantly reduced in the 3 day ligation group (0.040 ± 0.001 g, n ¼ 3), compared with nonligated control mice (0.055 ± 0.003 g, n ¼ 4). Following rapamycin treatment (0.056±0.002 g, n ¼ 4), mean gland weight was significantly (P ¼ 0.0008) greater compared with the ligation only group and was not different to unoperated controls. However, 5 day (0.040±0.005 g, n ¼ 3) and 7 day ligation (0.035±0.003 g, n ¼ 4) groups experienced a significant reduction compared with unoperated controls, which was not affected by rapamycin treatment (Figure 1 ).
All control groups showed similar gland weight measurements, with unoperated controls, rapamycin only and rapamycin vehicle-treated groups all showing no statistically significant difference.
By the end of the experiment, there was no statistically significant difference in body weight between experimental mice and the controls. For example, neither the 7 day ligation only (28.52±0.80 g, n ¼ 4) nor 7 day ligation with rapamycin treatment (31.47±1.18 g, n ¼ 7) differed significantly (P ¼ 0.22) from unoperated control (31.20 ± 1.49 g, n ¼ 4) mice body weights.
mTOR status
Complete inhibition of mTOR after 3 days of rapamycin treatment: Immunoblotting of phospho-S6 ribosomal protein, a downstream component of the mTOR substrate S6K1 in glandular homogenates revealed activation of S6K1 (and therefore activation of mTOR) in only the ligated state in the 3 day group. However, rapamycin treatment abolished this activation (Figure 2a and quantified in Figure 2c ).
Low expression of 4E-BP1 occurred, as the inactive isoform, in unoperated controls. Ligation revealed an increase in 4E-BP1 phosphorylation (and therefore activation of mTOR) in 3 day groups, as shown by the presence of a higher molecular weight band. Rapamycin treatment following ductal ligation abolished this activation, as represented by a visible reduction of isoforms (Figure 2b and quantified in Figure 2c ). Rapamycin only treated glands showed no expression of mTOR activity, identical to unoperated controls.
Incomplete inhibition of mTOR during long term rapamycin treatment: Immunoprobing of phospho-S6 ribosomal protein expression on 3, 5 and 7 day samples indicated mTOR activation in the ligated state. However, whilst rapamycin treatment abolished this activation after 3 days; a small protein band remained visible following rapamycin treatment after longer periods of ductal ligation (Figure 3a and quantified in Figures 3c and d) .
Duct ligation at 5 and 7 days increased 4E-BP1 protein expression and increased phosphorylation status compared with control, suggesting mTOR activation. Following ligation and rapamycin treatment for 5 days glandular homogenates revealed incomplete reduction of hyperphosphorylated status in all four mice examined. Seven day glandular homogenates also showed a visible increase in 4E-BP1 in ligation and a reduction of all isoforms post rapamycin treatment, however the upper isoform was only slightly reduced following rapamycin treatment (Figure 3b and quantified in Figures 3c  and d) . Rapamycin only treated glands showed no expression of mTOR substrate activity, identical to unoperated controls.
Western blotting of total mTOR in submandibular glands (Figure 3e and quantified in Figure 3f ) showed a marked increase in mTOR presence in ligated glands at all time points in comparison with controls. Rapamycin treatment greatly reduced total mTOR protein expression, but did not completely inhibit the presence of mTOR.
Short term rapamycin treatment rescues acinar atrophy: Periodic acid-Schiff's (PAS) staining of glandular homogenates indicated significant loss of acinar mucin with ligation at all time points (Figure 4 ). The 3 day ligation with rapamycin group showed only partial loss of mucin. Whereas 7 day rapamycin and ligation groups experienced complete loss of mucin, even post rapamycin treatment (Figure 4a ). Five day groups experienced variable results with partial loss of mucin in some animals ( Figure 4b ) and a complete loss in other animals.
Histological assessments: The haematoxylin and eosin staining (H&E) of both the ligation (Figure 5b ) and the ligation with rapamycin treatment (Figure 5c ) groups showed the presence of inflammatory cell infiltration, which were composed mainly of neutrophils and macrophages (as previously mentioned) 10, 11 in the connective tissue between the lobules and among the parenchymal elements after 3 days in comparison with controls ( Figure 5a ). Three day ligation groups also revealed shrunken acinar cells with loss of secretory granules and duct luminal dilation as they underwent degranulation, similar to previous findings. The H&E staining of the 7 days ligation and the 7 days ligation with rapamycin treatment, the 5 days ligation and the 5 days ligation with rapamycin treatment groups all revealed very similar results as ligation only glands with very little, to no differences.
Histomorphometric analysis indicated that the area of acini from ligated glands was significantly reduced at longer time periods, in both ligated and rapamycin-treated ligated samples, compared with unoperated control samples.
The histochemical staining of granular ducts by DMABnitrite showed loss of kallikrein, which is a marker for ductal function, 13 
Discussion
Our previous study suggested that mTOR was associated with the atrophic process during submandibular duct ligation. This study provides further evidence that mTOR is required for an autophagy-like process. However this study underlines the complexity of the in vivo regulation of mTOR and hints at its interaction with other pathways.
The ligation of the main excretory duct of the submandibular gland to study atrophy of the salivary glands has been well characterized in rats. 14, 15 As the first study of it's kind to use mice, this study found that the ligation of the excretory duct of the submandibular gland led to glandular atrophy as the gland underwent morphological, cellular and microscopic changes.
One such change is that mean submandibular gland weight was significantly reduced in all ligation groups in comparison with controls. Decreased volume and size of acinar cells with acinar and ductal degranulation may explain the significant decrease of glandular weights, although the increase of inflammatory cells infiltrating may have added to the gland weight initially.
Tissue morphology indicated that the glands of the 3 day ductal ligation group had shrunken acinar cells with loss of secretory granules, duct luminal dilation as they underwent degranulation and a general loss of cytoplasm in the duct cells. Similarly at 5 and 7 days of ligation most acinar cells had disappeared, ductal lumena were dilated with little cytoplasm left and there was an increased amount of connective tissue filled with inflammatory cell infiltrates.
The DMAB staining specific for stored tissue kallikrein of the granular convoluted ducts 16 of submandibular gland tissues at all time points post ligation indicated loss of kallikreincontaining secretory granules, corresponding with PAS staining of glandular homogenates, which showed a complete loss of mucin with ligation as previously demonstrated in ductligated submandibular gland of rats. 17 The absence of secretory glycoproteins indicates a lack of acinar cell synthetic activity.
Immunoprobing of the phospho-S6 ribosomal protein, which is phosphorylated at several sites by S6K1, 18, 19 and 4E-BP1 (another mTORC1 substrate) confirmed that mTOR is activated during ligation-induced atrophy of the salivary glands, which corresponds with the start of autophagic processes during ligation-induced atrophy. 10 Three days of rapamycin treatment following duct ligation showed a complete inhibition of mTOR, as shown by However, longer periods of rapamycin treatment post ligation surgery showed a loss of efficacy as gland weights were reduced, with morphological changes similar to ligation only and phosphorylation of S6rp and 4E-BP1 showing an incomplete inhibition of mTOR. Based on the results obtained in this experiment, rapamycin treatment is not believed to be effective in longer periods of administration and that Figure 3 Immunoblotting of phospho-S6 ribosomal protein (pS6rp) (a) and phospho-4E-BP1 protein (b) expression in submandibular glands during the longer 5 and 7 day periods of ligation and ligation with rapamycin treatment. pS6rp expression was abolished after 3 day rapamycin treatment post ductal ligation (L þ R) hence inhibiting mTOR expression. Five and seven day ligated (L) glandular homogenates revealed increased pS6r-protein expression. Rapamycin treatment during ductal ligation showed a visible reduction but not complete abolishment of expression at 5 and 7 days, indicating incomplete inhibition of mTOR. Phospho-4E-BP1 protein expression experienced a marked increase (the activated isoform bands), after ligation (L) for 5 and 7 days, indicating phosphorylation of mTOR. Rapamycin treatment following ductal ligation (L þ R) on 5 day showed a visible reduction of isoforms but not complete return to inactive isoform bands, indicating incomplete inhibition of mTOR, whereas 7 day ligation with rapamycin treatment revealed no visible reduction of 4E-BP1 protein expression. Densitometric analysis from the 5 (c) and 7 day experiments (d) show pS6rp and p4E-BP1 phosphorylation as a ratio of b-actin (*Po0.05). The bars represent the mean ± S.E.M. Protein expression of total mTOR in submandibular glands (e) in unoperated control, ligated and ligated with rapamycin-treated mice at increasing time points. Rapamycin treatment reduces total mTOR protein expression but does not completely inhibit mTOR, correlating with the pS6rp and 4E-BP1 protein expressions. Densitometric analysis showing mTOR expression as a ratio of b-actin (f) (*Po0.05). The bars represent the mean ± S.E.M. Beta actin (b-actin) was used as a loading control. Data represents results from at least three independent experiments rapamycin treatment only delays salivary gland atrophy following ductal ligation, as rapamycin is not a full inhibitor of mTOR, owing to the PI3K-negative feedback mechanism (which re-activates mTORC1 via the TSC1/2 complex). 20 It is possible rapamycin is ineffective against the negative feedback mechanism because rapamycin only inhibits mTORC1, 21 although there has been some evidence to suggest that the prolonged rapamycin treatment inhibits mTORC2 assembly, 22 which may be relevant to the changes observed from day 3 to day 5 in our study. Using a second generation mTOR inhibitor, Torin1, which is thought to inhibit all kinase-dependent functions of mTOR, 23 we obtained essentially identical results to rapamycin. It is possible that rapamycin had been effective in mTOR inhibition, yet S6K1 and 4E-BP1 were activated via mTOR-independent phosphorylation of S6K1 and 4E-BP1 (a mechanism suggested by other studies 24 ). Evidence from this study leads to the conclusion that inhibition of mTOR can delay ligation-induced atrophy of salivary glands, however only affecting acinar, but not ductal, atrophic processes.
Materials and Methods Submandibular duct ligation surgery. A total of 37 adult female ICR mice were obtained from Charles Rivers Laboratories (Margate, UK); weighing an average of 20-25 g upon arrival. On arrival mice were housed in groups of four, with food and water provided ad libitum. A 12 h light-dark cycle was maintained at a constant temperature of 20-22 1C. Environmental enrichments (tunnels and nesting material) were provided in each cage. Animals were allowed to acclimatize to their new environment for 1 week before experimental procedures. All animal studies and procedures were conducted in accordance with UK Home Office Animal (Scientific Procedures) Act 1986. The mice were weighed and anaesthetized with xylazine (5 mg/Kg) /ketamine (25 mg/Kg) i.p. injections, and placed on a controlled heating pad to maintain the body temperature. The depth of anesthesia was assessed by pedal reflex. Held in the supine position with the neck extended, a skin incision B0.5 cm long was made in the midline of the neck (on the medial side of the angle of the mandible), the fat surrounding the salivary glands was cleared via blunt dissection and subsequently the left submandibular gland duct was isolated. The left submandibular excretory duct was ligated using a 6-0 Ethicon suture (Johnson and Johnson Intl, Brussels, Belgium).
After ligation of the main secretory duct, the neck was sutured. The mice were allowed to recover from anaesthesia in a cage maintained in a warm room and were administered analgeics (buprenorphine, 10 mg/kg) post surgery. Aseptic conditions were used throughout the surgical procedure of duct ligation to reduce the risk of infection.
Submandibular gland samples were collected for analysis. The samples were designated in to groups: the control and experimental groups.
The control groups were either unoperated controls (n ¼ 4), receiving drug vehicle for 3 days (n ¼ 4) or receiving rapamycin injections for 3 days (n ¼ 4).
The experimental groups underwent unilateral submandibular excretory duct ligation surgery under recovery anaesthesia for either 3 (n ¼ 3), 5 (n ¼ 3) or 7 days (n ¼ 4), or they underwent surgery whilst also receiving 5 mg/kg per day of rapamycin (subcutaneous (s.c.)) for 3 (n ¼ 4), 5 (n ¼ 4) or 7 days (n ¼ 7) post surgery.
At the end of experiments, submandibular glands were removed, weighed and tissues were either fixed in 4% formalin overnight or snap frozen in liquid nitrogen for biochemical analysis.
Contralateral submandibular glands from the experimental mice were not collected as controls, as they experience compensative hyperplasia when the other gland is extirpated or ligated. 25, 26 Animal body weights were recorded daily. Mice were sacrificed by an overdose of pentobarbitone.
Rapamycin treatment. Rapamycin was resuspended in a stock solution at 20 mg/ml in DMSO and stored at À 20 1C until used. For vehicle controls, animals were injected (s.c.) with 200 ml of rapamycin injection vehicle (10% polyethylene glycol 400 and 17% tween-80). The experimental groups received s.c. injections, each injection consisted of 5 mg/kg per day of Rapamycin diluted in 200 ml of injection vehicle (10% polyethylene glycol 400 and 17% tween-80), all as previously demonstrated. 27 This particular dose was chosen because of the efficacy and comparative effectiveness of the inhibition of mTOR signaling by rapamycin as shown in previous studies, 28, 29 furthermore, in preparatory undertakings for this study, this was found to be the maximum dose without seeing significant body weight loss. No toxicity or adverse effects of the compound were identified in this experiment, in accordance with the previous rapamycin studies. 29, 30 Histochemical staining of tissue samples. Submandibular glands were embedded in wax and 5 mm thick sections were cut and mounted on superfrost plus-coated slides. General morphology of the tissue sections was assessed by H&E staining. The secretory granules inside acinar cells were identified by AB/PAS staining. Granular ductal kallikreins were stained using DMAB, as previously demonstrated. 10 Morphometric analysis. From the submandibular gland samples prepared for histochemical staining, 20 acini per sample were randomly selected and the mean area (mm 2 ) was measured using Leica TCS SP2 confocal microscope software version 2.1 (Leica Microsystems, Heidelberg, Germany).
Tissue preparation and immunoblotting. Tissue specimens stored at À 80 1C were homogenized in 19 volumes (wt/vol) of ice-cold homogenization buffer (1% Triton X-100, 1 mM EDTA, and a 1% v/v dilution of protease inhibitor cocktail set 1 (Merck Chemicals Ltd, Nottingham, UK) using an Ultra-Thurrax homogenizer (IKA Labortechnik, Staufen, Germany).
SDS-PAGE of samples was carried out (NUPAGE Novex Bis-Tris 4-12% gel; Life technologies, Paisley, UK). Proteins resolved by electrophoresis were then electroblotted onto 0.45 mm nitrocellulose membranes (Anderman and Co., Kingston-Upon-Thames, UK).
The procedure followed for immunoblotting is that which has been previously established. 31 Membranes were imaged in a ChemiDoc Imaging System (BIORAD Laboratories Ltd, Hertfordshire, UK), with optimized exposure times and the built-in highsensitivity blot detection which highlights over-saturated pixels, to obtain ideal exposure in images of the protein bands.
Band intensity from immunoblots were quantified using the image analysis software ImageJ version 1.46 (NIH, Maryland, MD, USA), with each bar representing the mean normalized from the ratio of b-actin ±S.E.M.
Antibodies. Anti-phospho-4E-BP1 (1 : 1000 for western blotting), antiphospho-S6 ribosomal protein (1 : 1000 for western blotting), anti-mTOR (1 : 1000 for western blotting) were obtained from Cell Signaling Technology (Hertfordshire, UK) and anti-b-actin was from Sigma-Aldrich (St. Louis, MO, USA).
Secondary antibodies included polyclonal goat anti-mouse immunoglobulin-HRP (P0447) and polyclonal goat anti-rabbit immunoglobulin-HRP (P0448) from Dako Ltd (Ely, UK). 
